Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility

MT Newswires Live2025-01-17

Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.

ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.

The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.

The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.

Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2504972351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-17 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504972351","market":"hk","top_or_hot":-1,"title":"Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility","media":"MT Newswires Live","content":"<html><body><p> Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.</p><p>ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.</p><p>The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.</p><p>The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.</p><p>Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Samsung Biologics Ventures in Antibody-Drug Conjugate Market with New Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-17 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.</p><p>ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.</p><p>The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.</p><p>The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.</p><p>Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2504972351","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504972351","pubTimestamp":1737080302,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Samsung Biologics  entered the antibody-drug conjugate  sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.The company has deepened its collaboration with LigaChem Biosciences , signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4080":"零售业房地产投资信托","ADC":"艾格里房产","ADC.AU":"ACDC Metals Ltd","BK7095":"多种金属与采矿","BK4231":"零售房地产信托"},"translate_title":"市场热议：三星生物制品公司通过新工厂进军抗体药物偶联物市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"ADC.AU":1},"content_text":"Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504972351","isCrawlerRequest":true}